Breaking News Instant updates and real-time market news.

HALO

Halozyme

$15.98

2.8 (21.24%)

, BMY

Bristol-Myers

$62.69

0.21 (0.34%)

06:40
09/15/17
09/15
06:40
09/15/17
06:40

Halozyme price target raised to $20 from $17 at Deutsche Bank

Deutsche Bank analyst Andrew Peters raised his price target for Halozyme (HALO) to $20 saying he's bullish following the new Enhanze partnership. Yesterday's dual announcements for additional Enhanze collaborations are "clear positives" for the stock, Peters tells investors in a research note. He says the size of the Bristol-Myers Squibb deal, including the upfront payment, is larger than expected. The analyst reiterates a Buy rating on Halozyme.

HALO

Halozyme

$15.98

2.8 (21.24%)

BMY

Bristol-Myers

$62.69

0.21 (0.34%)

  • 24

    Sep

  • 25

    Sep

  • 18

    Oct

  • 26

    Oct

  • 09

    Nov

  • 05

    Mar

HALO Halozyme
$15.98

2.8 (21.24%)

09/14/17
PIPR
09/14/17
NO CHANGE
Target $26
PIPR
Overweight
Halozyme price target raised to $26 from $20 at Piper Jaffray
04/17/17
BMOC
04/17/17
INITIATION
Target $14
BMOC
Market Perform
Halozyme initiated with a Market Perform at BMO Capital
BMO Capital initiated Halozyme with a Market Perform and a $714 price target.
03/30/17
DBAB
03/30/17
NO CHANGE
Target $17
DBAB
Buy
Halozyme price target raised to $17 from $15 at Deutsche Bank
Deutsche Bank analyst Andrew Peters raised his price target for Halozyme to $17 saying the positive, "unanimous and uncontroversial" FDA Advisory Committee meeting for Rituxan-SC highlights the "strong potential" for the broader Enhanze platform. The analyst reiterates a Buy rating on the shares.
01/06/17
SBSH
01/06/17
DOWNGRADE
Target $14
SBSH
Neutral
Halozyme downgraded to Neutral from Buy at Citi
Citi analyst Joel Beatty downgraded Halozyme Therapeutics to Neutral saying the "mixed" Phase 2 pancreatic cancer data for PEGPH20 suggested the market opportunity is smaller than previously thought. The analyst believes the shares are now fairly valued. He keeps a $14 price target for the name.
BMY Bristol-Myers
$62.69

0.21 (0.34%)

09/12/17
09/12/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Bristol-Myers (BMY) downgraded to Neutral from Long-Term Buy at Hilliard Lyons with analyst Kurt Kemper citing share appreciation as shares have approached his previous $65 price target. 2. Bunge (BG) downgraded to Hold from Buy at Vertical Group citing the acquisition of 70% interest in IOI Loders Croklaan. 3. Advance Auto Parts (AAP) downgraded to Sell from Neutral at Citi with analyst Kate McShane saying the company's turnaround seems to be taking longer given the number of issues to fix, and its cost savings are unlikely to impact earnings given its needed investments. 4. Precision Drilling (PDS) downgraded to Neutral from Overweight at JPMorgan. 5. Nucor (NUE) and Steel Dynamics (STLD) were downgraded to Equal Weight from Overweight at Morgan Stanley. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/12/17
HDLY
09/12/17
DOWNGRADE
Target $65
HDLY
Neutral
Bristol-Myers downgraded to Neutral from Long-Term Buy at Hilliard Lyons
Hilliard Lyons analyst Kurt Kemper downgraded Bristol-Myers to Neutral due to share appreciation as shares have approached his previous $65 price target.
08/31/17
MSCO
08/31/17
NO CHANGE
MSCO
Overweight
Incyte melanoma data exceeded expectations, says Morgan Stanley
Morgan Stanley analyst Andrew Berens said the data on the use of an epacadostat/PD- 1 combo in melanoma treatment presented in an ESMO abstract exceeds expectations and "leaves little doubt" about the combination's efficacy. The analyst, who added that Incyte's (INCY) PFS data exceeds that of a combination of Bristol-Myers' (BMY) Opdivo with Yervoy, keeps an Overweight rating on Incyte and said the data bodes well for the company's Phase 3 program.
08/16/17
LEER
08/16/17
NO CHANGE
Target $34
LEER
Outperform
Leerink sees competitor setback in RCC opportunity for Exelixis
Leerink analyst Michael Schmidt notes that Bristol-Myers (BMY) reported top-line results from the Phase III CheckMate-214 trial investigating Opdivo in combination with Yervoy versus Sutent in intermediate and poor-risk patients with previously untreated advanced or metastatic renal cell carcinoma, or RCC. While directionally positive, the trial missed the co-primary endpoint of improving progression-free survival with statistical significance, he notes, adding that this raises the regulatory bar for Bristol-Myers' IO combination at least until positive overall survival data are available likely in mid-2019, which he thinks will be positively received by Exelixis (EXEL) investors. Following the news, Schmidt believes Exelixis continues to look well positioned in RCC, He reiterates an Outperform rating and $34 price target on the latter's shares.

TODAY'S FREE FLY STORIES

AGCO

Agco

$73.31

0.34 (0.47%)

06:41
09/21/17
09/21
06:41
09/21/17
06:41
Recommendations
Agco analyst commentary  »

Agco long-term margin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

06:41
09/21/17
09/21
06:41
09/21/17
06:41
Technical Analysis
S&P 500: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDX

Market Vector Gold Miners

$23.50

-0.35 (-1.47%)

06:41
09/21/17
09/21
06:41
09/21/17
06:41
Technical Analysis
Market Vector Gold Miners: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$24.32

0.12 (0.50%)

06:40
09/21/17
09/21
06:40
09/21/17
06:40
Periodicals
GE shutting down corporate jet fleet in bid to cut costs, WSJ reports »

GE is planning to shut…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

GLD

SPDR Gold Trust

$123.62

-1 (-0.80%)

06:40
09/21/17
09/21
06:40
09/21/17
06:40
Technical Analysis
SPDR Gold Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUGT

Direxion Gold Miners Bull

$33.69

-1.66 (-4.70%)

06:40
09/21/17
09/21
06:40
09/21/17
06:40
Technical Analysis
Direxion Gold Miners Bull: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNUG

Direxion Daily Jr Gld Mnrs Bull 3X Shrs

$18.82

-1.03 (-5.19%)

06:39
09/21/17
09/21
06:39
09/21/17
06:39
Technical Analysis
Direxion Daily Jr Gld Mnrs Bull 3X Shrs: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DUST

Direxion Daily Gold Miners Bear 3X ETF

$24.34

1.09 (4.69%)

06:39
09/21/17
09/21
06:39
09/21/17
06:39
Technical Analysis
Direxion Daily Gold Miners Bear 3X ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JDST

Direxion Daily Junior Gold Miners Index Bear 3x Shares

$54.48

2.67 (5.15%)

06:38
09/21/17
09/21
06:38
09/21/17
06:38
Technical Analysis
Direxion Daily Junior Gold Miners Index Bear 3x Shares: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VXX

iPath S&P 500 VIX Short-Term Futures

$40.98

0.07 (0.17%)

06:37
09/21/17
09/21
06:37
09/21/17
06:37
Technical Analysis
iPath S&P 500 VIX Short-Term Futures: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XIV

VelocityShares Daily Inverse VIX Short-Term ETN

$93.36

-0.23 (-0.25%)

06:37
09/21/17
09/21
06:37
09/21/17
06:37
Technical Analysis
VelocityShares Daily Inverse VIX Short-Term ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TVIX

VelocityShares Daily 2x VIX Short-Term ETN

$12.45

0.06 (0.48%)

06:36
09/21/17
09/21
06:36
09/21/17
06:36
Technical Analysis
VelocityShares Daily 2x VIX Short-Term ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SVXY

ProShares Short VIX Short-Term Futures

$89.64

-0.09 (-0.10%)

06:36
09/21/17
09/21
06:36
09/21/17
06:36
Technical Analysis
ProShares Short VIX Short-Term Futures: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALV

Autoliv

$122.59

1.04 (0.86%)

06:36
09/21/17
09/21
06:36
09/21/17
06:36
Recommendations
Autoliv analyst commentary  »

Autoliv price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

USO

United States Oil Fund

$10.24

0.13 (1.29%)

06:35
09/21/17
09/21
06:35
09/21/17
06:35
Technical Analysis
United States Oil Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOP

SPDR Oil Exploration and Production Fund

$32.86

0.68 (2.11%)

06:35
09/21/17
09/21
06:35
09/21/17
06:35
Technical Analysis
SPDR Oil Exploration and Production Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGAZ

VelocityShares 3x Inv Natural Gas ETN

$21.73

0.61 (2.89%)

06:34
09/21/17
09/21
06:34
09/21/17
06:34
Technical Analysis
VelocityShares 3x Inv Natural Gas ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UGAZ

VelocityShares 3x Long Natural Gas ETN

$13.20

-0.36 (-2.65%)

06:34
09/21/17
09/21
06:34
09/21/17
06:34
Technical Analysis
VelocityShares 3x Long Natural Gas ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMD

AMD

$13.74

0.62 (4.73%)

, NVDA

Nvidia

$185.84

-1.51 (-0.81%)

06:34
09/21/17
09/21
06:34
09/21/17
06:34
Recommendations
AMD, Nvidia, Tesla analyst commentary  »

Tesla partnership would…

AMD

AMD

$13.74

0.62 (4.73%)

NVDA

Nvidia

$185.84

-1.51 (-0.81%)

TSLA

Tesla

$373.91

-1.19 (-0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

EWZ

MSCI Brazil Index

$43.19

0.13 (0.30%)

06:34
09/21/17
09/21
06:34
09/21/17
06:34
Technical Analysis
MSCI Brazil Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFA

iShares MSCI EAFE Index Fund

$68.32

-0.15 (-0.22%)

06:33
09/21/17
09/21
06:33
09/21/17
06:33
Technical Analysis
iShares MSCI EAFE Index Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNK

SPDR Barclays High Yield Bond

$37.21

-0.01 (-0.03%)

06:33
09/21/17
09/21
06:33
09/21/17
06:33
Technical Analysis
SPDR Barclays High Yield Bond: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SJB

ProShares Short High Yield

$23.19

0.0092 (0.04%)

06:32
09/21/17
09/21
06:32
09/21/17
06:32
Technical Analysis
ProShares Short High Yield: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUO

AU Optronics

$4.19

-0.03 (-0.71%)

06:32
09/21/17
09/21
06:32
09/21/17
06:32
Periodicals
AU Optronics to continue 'smart investment' policy, DigiTimes reports »

AU Optronics Chairman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HYG

iShares iBoxx $ High Yield Corporate Bond

$88.45

-0.01 (-0.01%)

06:32
09/21/17
09/21
06:32
09/21/17
06:32
Technical Analysis
iShares iBoxx $ High Yield Corporate Bond: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.